Selected References
- Bristol-Myers Squibb. 2019. Available information online at https://clinicaltrials.gov/ct2/show/record/NCT01087125?view=record
- R. Squibb and Sons, L.L.C. 2019. Orencia product lab. Available at https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb
- Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 45(3):351-6.
- Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 22;71(15):1973-87.
- Ojeda-Uribe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 32(5): 695-700.
- Orencia Prescribing Information. Available online at https://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed 12/2017.
- Ostensen M and Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 23(3):293-8.
- Partlett R and Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int. 31(4):445-9.
- Pham T., et al. 2012. Abatacept therapy and safety management. Joint Bone Spine 79 Suppl 1:3-84.
